Influenza Neuraminidase

Influenza Neuraminidase Photo
The neuraminidase inhibitors zanamivir and oseltamivir interfere with the release of progeny influenza virus from infected host cells, a process that prevents infection of new host cells and thereby halts the spread of infection in the respiratory tract. The neuraminidase inhibitors are effective against all neuraminidase subtypes and, therefore, against all strains of influenza, a key point in epidemic and pandemic preparedness and an important advantage over the adamantanes, which are effective only against sensitive strains of influenza A. These new drugs, if used properly, have great potential for diminishing the effects of influenza infection. The global neuraminidase inhibitor susceptibility network (NISN), which coordinates the analysis of clinical isolates collected through the World Health Organization's surveillance network, found no influenza isolates with spontaneous resistance to neuraminidase inhibitors.

Are you interested in

Mail us at

For Program Enquiry
More details about

Authorization Policy

Science Policy Interface topics

       1.  Influenza is a moving target and a secret killer

2.   Prevention and treatment of influenza

3.   Addressing influenza in practice: who’s involved?

4.   Implementation of vaccination policies: success stories and hurdles

5.   Influenza preparedness: what can we learn from other virus outbreaks?

6.   Reaching out to people at risk

7.   Influenza prevention in developing countries: a global responsibility

Copyright © 2018-2019 Allied Academies, All Rights Reserved.